Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group.

Trial Profile

Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2014

At a glance

  • Drugs Fotemustine (Primary) ; Fotemustine (Primary)
  • Indications Liver metastases; Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2014 Results published in the Annals of Oncology.
    • 12 Oct 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2004-002245-12).
    • 13 Jul 2012 Additional lead trial center identified as reported by CliniclaTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top